Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,264 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pathways Clear all
Terminated Phase 1 Interventional

A Study of Niclosamide in Patients With Resectable Colon Cancer

NCT02687009
View directory record Official record
Conditions
Colon Cancer
Interventions
Niclosamide
Drug
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 17, 2026, 10:18 AM EDT
Enrolling by invitation Not applicable Interventional

Connectomic Guided DBS for Parkinson's Disease

NCT06618157
View directory record Official record
Conditions
Parkinson Disease, Tremor, Dyskinesias
Interventions
Cerebellothalamic optimized deep brain stimulation, Pallidothalamic optimized deep brain stimulation, No deep brain stimulation, Usual care deep brain stimulation
Device · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 17, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

NCT02632409
View directory record Official record
Conditions
Various Advanced Cancer
Interventions
Nivolumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
33
States / cities
Anchorage, Alaska • Tucson, Arizona • Clovis, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 17, 2026, 10:18 AM EDT
Withdrawn No phase listed Observational

Enhanced Recovery After Cesarean Hysterectomy

NCT04205149
View directory record Official record
Conditions
Post-operative Recovery for Cesarean Hysterectomy Patients
Interventions
ERAS post-operative pathway
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 17, 2026, 10:18 AM EDT
Completed No phase listed Observational

Development of a Hospital Service That Uses Critical Pathway (Protocolized) Care Plans to Provide High-Quality, High-Reliability, Evidence-Based Medical Care

NCT00275587
View directory record Official record
Conditions
Critical Pathways
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 17, 2026, 10:18 AM EDT
Terminated Not applicable Interventional

A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD)

NCT02479906
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Deep TMS System, Sham Treatment
Device
Lead sponsor
Brainsway
Industry
Eligibility
22 Years to 68 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 17, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Results available

Effect of Galantamine on Inflammation and Cognition

NCT03384784
View directory record Official record
Conditions
HIV Associated Cognitive Motor Complex
Interventions
Galantamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 17, 2026, 10:18 AM EDT
Active, not recruiting Not applicable Interventional

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

NCT00579514
View directory record Official record
Conditions
Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer
Interventions
PCR/PCR/LDR Strategy
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
21,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 17, 2026, 10:18 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluating Novel Therapies in ctDNA Positive GI Cancers

NCT05482516
View directory record Official record
Conditions
Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 10:18 AM EDT
Completed Phase 1 Interventional

DAY101 In Gliomas and Other Tumors

NCT03429803
View directory record Official record
Conditions
Low-grade Glioma
Interventions
DAY101
Drug
Lead sponsor
Karen D. Wright, MD
Other
Eligibility
1 Year to 25 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 17, 2026, 10:18 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
BMS-986365, Enzalutamide, Abiraterone, Docetaxel, Predinsone/Prednisolone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Male only
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
48
States / cities
Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 17, 2026, 10:18 AM EDT
Completed Phase 3 Interventional

The Effects of Atorvastatin in Patients With Atherosclerosis

NCT00115817
View directory record Official record
Conditions
Atherosclerosis
Interventions
Atorvastatin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2007 · Synced Oct 17, 2026, 10:18 AM EDT
Recruiting Phase 2 Interventional

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT05538091
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor, Hedgehog Inhibitor
Interventions
Vismodegib, Atezolizumab
Drug
Lead sponsor
Ronald Buckanovich
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 17, 2026, 10:18 AM EDT
Completed Phase 4 Interventional Results available

Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade

NCT01335542
View directory record Official record
Conditions
Readiness to Discharge
Interventions
Peri-Articular Injection, Epidural Pathway (PCEA+FNB)
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 17, 2026, 10:18 AM EDT
Recruiting Not applicable Interventional

Hydrus® Microstent New Enrollment Post-Approval Study

NCT04553523
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Hydrus Microstent, Cataract surgery, Monofocal IOL
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
22
States / cities
Irvine, California • Sacramento, California • Loveland, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 10:18 AM EDT
Active, not recruiting Not applicable Interventional

Evaluating Pathways Mutual Gaze Protocol on Social Skills in Young Children Suspected of Autism

NCT06596226
View directory record Official record
Conditions
Autism
Interventions
Pathways Parent Mediated Intervention, Pathways Parent Mediated Intervention without Mutual Gaze
Behavioral
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
16 Months to 30 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 10:18 AM EDT
Terminated Phase 1 Interventional Results available

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

NCT04249843
View directory record Official record
Conditions
Solid Tumor, B-Raf Mutation-Related Tumors
Interventions
Brimarafenib
Drug
Lead sponsor
MapKure, LLC
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Beverly Hills, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 17, 2026, 10:18 AM EDT
Completed No phase listed Observational

A MRI Study of Visual and Motor Pathways in Premature Infants

NCT01514747
View directory record Official record
Conditions
Premature Birth
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
2 Months to 5 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 17, 2026, 10:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

NCT03310619
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions
JCAR017, Durvalumab, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 17, 2026, 10:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

NCT06566079
View directory record Official record
Conditions
Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
Interventions
ISM6331
Drug
Lead sponsor
InSilico Medicine Hong Kong Limited
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Denver, Colorado • Chicago, Illinois • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 17, 2026, 10:18 AM EDT
Completed Phase 4 Interventional

Opioid Free Anesthesia and Bariatric Surgery

NCT04144153
View directory record Official record
Conditions
Postoperative Quality of Recovery
Interventions
Opioid Free Total Intravenous Anesthesia, Total Intravenous anesthesia with opioid
Combination Product
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 10:18 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Improving Exercise Rehabilitation Efficacy Outcomes Veterans Peripheral Artery Disease

NCT05648630
View directory record Official record
Conditions
Peripheral Artery Disease (D058729), Oxidative Stress (D018384), Inflammation (D007249)
Interventions
PB125, Placebo, Exercise Rehabilitation
Dietary Supplement · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 17, 2026, 10:18 AM EDT
Completed Phase 1 Interventional Results available

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

NCT03307785
View directory record Official record
Conditions
Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
Interventions
Niraparib, TSR-042, Carboplatin-Paclitaxel, Bevacizumab, TSR-022, Carboplatin-Pemetrexed, Carboplatin-Nab-Paclitaxel
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Scottsdale, Arizona • Encinitas, California • San Marcos, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 17, 2026, 10:18 AM EDT
Terminated Phase 2 Interventional Results available

Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

NCT00694603
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Cetuximab
Drug
Lead sponsor
Lecia V. Sequist
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 17, 2026, 10:18 AM EDT